Congestive Heart Failure Drugs Market (2024 - 2030)

Congestive Heart Failure Drugs Market Summary

Another major factor facilitating growth is the rising burden of diseases such as obesity, diabetes, hypertension, chronic pulmonary diseases, and renal disease as these are considered CHF-associated prominent comorbidities. The aging population is a significant contributor to the rise in CHF prevalence. As individuals age, they are more susceptible to heart-related conditions, leading to increased demand for CHF medications. According to World Heart Federation, cardiovascular diseases are a major global health problem, affecting over half a billion people and causing millions of deaths each year. The increasing prevalence of risk factors such as obesity, diabetes, hypertension, and sedentary lifestyles contributes to the higher incidence of CHF. Moreover, organizations dedicated to cardiovascular health, such as the World Heart Organization (WHO), American Heart Association (AHA), and various national heart foundations, actively engage in awareness initiatives.

Continuous research and development efforts are leading to the introduction of new and more effective CHF drugs, expanding treatment options. Newer drugs often offer better efficacy and safety profiles, driving market growth. Rising healthcare expenditures are enabling greater access to CHF treatments. Expanding healthcare coverage and infrastructure in developing countries is increasing the market potential. Growing awareness about heart health and the importance of early detection and treatment is further fueling the market growth.

Drug Insights

ACE inhibitors held the largest share of 28.6% in 2023. It is the first treatment choice for treating CHF patients. It includes drugs including Epaned (enalapril), Vasotec, Zestril, Qbrelis, captopril and Prinivil (lisinopril).

Angiotensin 2 receptor blockers (ARBs) are anticipated to witness the significant CAGR of 10.2% over the forecast period. ARBs provide an alternative for patients who cannot tolerate ACE inhibitors due to cough or angioedema, thereby expanding the treatment options available for CHF management.

Product Insights

The tablets segment dominated the market with 38.2% of revenue share in 2023. The convenience and ease of administration offered by tablets have made them a preferred choice for patients managing chronic conditions such as CHF. Moreover, advancements in drug formulation and delivery systems have led to the development of tablets with improved bioavailability and sustained release properties, enhancing treatment efficacy. In addition, the rising geriatric population, a primary demographic for CHF, often prefers tablets due to ease of use, contributing to market growth.

The injection segment is anticipated to witness significant CAGR of 15.2% over the forecast period. This is due to the need for rapid onset of action and higher drug concentrations often required in acute CHF cases. Furthermore, the development of long-acting injectable formulations is gaining traction, reducing the frequency of administration for patients and improving adherence. While traditionally associated with hospital settings, the increasing availability of self-injectable formulations is expanding the use of injections in the outpatient setting, contributing to market growth.

Distribution Channel Insights

Hospital pharmacies dominated the market with 55.6% share in 2023. These pharmacies are equipped to handle complex drug regimens often required for CHF patients, ensuring timely medication access. The increasing number of CHF patients requiring hospitalization for acute exacerbations or elective procedures drives demand for these drugs through hospital pharmacies.

Retail pharmacies are projected to grow at a CAGR of 15.3% over the forecast period. As CHF management increasingly shifts towards outpatient settings, the accessibility and convenience offered by retail pharmacies have become crucial.

Regional Insights

North America congestive heart failure drugs market held the largest share of 37.6% in 2023. This is owing to the rise in patient awareness, high disease burden, and increased healthcare expenditure.

U.S. Congestive Heart Failure Drugs Market Trends

The U.S. congestive heart failure drugs market dominated the North America market in 2023 due to large geriatric population, sedentary lifestyle, and increasing obesity rates. The presence of key pharmaceutical players, coupled with extensive healthcare coverage, fosters a favorable environment for drug development and market expansion. According to National Institutes of Health, the number of Americans living with heart failure is currently 6.7 million and is projected to increase by nearly a third to 8.5 million by 2030.

Europe Congestive Heart Failure Drugs Market Trends

Europe congestive heart failure drugs market was identified as a lucrative region in 2023. As an aging population increases, the risk of heart diseases increases. Furthermore, the region's robust healthcare infrastructure, coupled with advancements in diagnostic technologies, enables early disease detection and improved patient management, driving demand for CHF drugs. The UK congestive heart failure drugs market is expected to grow rapidly in the coming years. According to British Heart Foundation, the number of people living with heart and circulatory diseases in the UK is currently 7.6 million.

Asia Pacific Congestive Heart Failure Drugs Market Trends

Asia Pacific market is anticipated to witness fastest growth in the global congestive heart failure drugs market. The region's burgeoning population, coupled with increasing life expectancy, is leading to a rise in the elderly population susceptible to CHF.

The congestive heart failure drugs market in India held a substantial market share due to country's large population, rising disposable incomes, and increasing healthcare expenditure. In July 2023, AstraZeneca Pharma India received approval from the Indian drug regulator to import dapagliflozin tablets for treating heart failure. This move could benefit a large number of heart failure patients in India.

Key Congestive Heart Failure Drugs Company Insights

Some of the key companies in the Congestive Heart Failure (CHF) drugs market include Bayer AG, Novartis AG, Merck & Co., Inc., AstraZeneca, Bristol-Myers Squibb Company, Pfizer, Inc., Johnson & Johnson Services, Inc. and others. Key players are trying to acquire a greater share through collaborations, partnerships, regional expansions, and other strategic initiatives.

• Bayer AG is a German multinational corporation that operates in the fields of pharmaceuticals, consumer health products, and biotechnology. In the congestive heart failure drugs market, Bayer AG has established itself as a significant player by offering innovative therapies aimed at improving patient outcomes.

Recent Developments

• In May 2024, Novartis AG launched Entresto Granular Tablets, a new formulation of its heart failure drug specifically designed for pediatric patients. This is the first ARNI treatment option for children with chronic heart failure. The drug has been approved for use in children with chronic heart failure, a condition often caused by congenital heart disease or cardiomyopathy.

• In March 2024, Novo Nordisk A/S entered into an agreement to acquire Cardior Pharmaceuticals, a company specializing in RNA-based therapies for heart disease. This acquisition is expected to strengthen Novo Nordisk's position in the cardiovascular disease market.

• In March 2024, Bayer AG acquired the exclusive rights to market acoramidis in Europe. It is a potent & selective small molecule, orally administered TTR stabilizer for treating patients who are suffering from ATTR CM.

Congestive Heart Failure Drugs Market